Skip to main content
Mark Walters, MD, Pediatric Hematology & Oncology, Oakland, CA

Mark C Walters MD


Professor of Pediatrics, UCSF and Jordan Family Director, BMT Program, UCSF Benioff Children's Hosp, Oakland

Join to view full profile
  • 747 52nd StDept Of Hematology/OncologyOakland, CA 94609

  • Phone+1 510-428-3374

  • Fax+1 510-601-3916

Dr. Walters is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Summary

  • Dr. Mark Walters is a Pediatric Hematologist & Oncologist who is chief of pediatric hematology at UCSF School of Medicine. He completed his medical training at the University of California San Diego School of Medicine, followed by a fellowship in Pediatric Hematology/Oncology at the University of Washington. His expertise includes hemoglobinopathies, thalassemias, hematopoietic stem cell transplantation, bone marrow transplantation, and sickle-cell anemia. He is involved in several clinical trials, including those focused on sickle cell disease and gene editing/gene therapy. Dr. Walters has authored multiple publications in reputable journals such as NEJM, NEJM Evidence, Lancet, and Blood Advances, with his work being cited by other publications numerous times.

Education & Training

  • University of Washington
    University of WashingtonFellowship, Pediatric Hematology/Oncology, 1988 - 1992
  • University of California San Diego School of Medicine
    University of California San Diego School of MedicineClass of 1985

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1999 - 2027
  • NV State Medical License
    NV State Medical License 2007 - 2023
  • KY State Medical License
    KY State Medical License 2007 - 2021
  • MA State Medical License
    MA State Medical License 2007 - 2020
  • RI State Medical License
    RI State Medical License 2009 - 2020
  • NJ State Medical License
    NJ State Medical License 2007 - 2019
  • PA State Medical License
    PA State Medical License 2007 - 2010
  • Pediatric Hematology-Oncology
    American Board of Pediatrics Pediatric Hematology-Oncology
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • The Safety and Efficacy of Clofarabine in Combination with High-Dose Cytarabine and Total Body Irradiation Myeloablative Conditioning and Allogeneic Stem Cell Transpla...  
    Stacey Zahler, Mitchell S Cairo, Jennifer Krajewski, M Fevzi Ozkaynak, Alexandra C Cheerva, Theodore B Moore, Alfred P Gillio, Mark C Walters, Nature

Abstracts/Posters

  • Northstar-2: Updated Safety and Efficacy Analysis of Lentiglobin Gene Therapy in Patients with Transfusion-Dependent _-Thalassemia and Non-_0/_0 Genotypes
    Mark C. Walters, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • The Relationships between Target Gene Transduction, Engraftment of HSCs and RBC Physiology in Sickle Cell Disease Gene Therapy
    Mark C. Walters, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Preliminary Results of a Phase 1/2 Clinical Study of Zinc Finger Nuclease-Mediated Editing of BCL11A in Autologous Hematopoietic Stem Cells for Transfusion-Dependent B...
    Mark C. Walters, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

  • Exploring the Drivers of Potential Clinical Benefit in Initial Patients Treated in the Hgb-206 Study of Lentiglobin for Sickle Cell Disease (SCD) Gene Therapy 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Advancing Science in Sickle Cell Disease: Implications for the Future of Care 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Significantly Improved Long Term Health Related Quality of Life (HRQL) and Neurocognition Following Familial Haploidentical Stem Cell Transplantation (HISCT) Utilizing... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Honoring Dr. John Zaia: A Legacy of Science, Leadership, and Kindness
    Honoring Dr. John Zaia: A Legacy of Science, Leadership, and KindnessFebruary 27th, 2025
  • VUMC Part of New Study Validating Curative Therapy for Sickle Cell Disease
    VUMC Part of New Study Validating Curative Therapy for Sickle Cell DiseaseFebruary 27th, 2025
  • Novel Gene Therapy Trial for Sickle Cell Disease Launches
    Novel Gene Therapy Trial for Sickle Cell Disease LaunchesNovember 22nd, 2024

Grant Support

  • NRSA Training CoreUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2023–2028
  • Hematopoietic Cell Therapy For Young Adults With Severe Sickle Cell DiseaseNational Heart, Lung, And Blood Institute2011
  • Northern California Consortium For Sickle Cell DiseaseNational Heart, Lung, And Blood Institute2006–2008
  • Induction Of Stable Chimerism For Sickle Cell AnemiaNational Heart, Lung, And Blood Institute2001–2004
  • Mechanisms Of Globin Gene SilencingNational Heart, Lung, And Blood Institute1998–1999

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: